[F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [F]Fluciclovine.

Aim: The objective of this study was to compare the detection rates of [F]PSMA-1007 and [F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.

Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas.

Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may offer a new perspective.

Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer.

Current imaging modalities frequently misjudge disease stage in colorectal, gastric and pancreatic cancer. As treatment decisions are dependent on disease stage, incorrect staging has serious consequences. Previous preclinical research and case reports indicate that prostate-specific membrane antigen (PSMA)-targeted PET/CT imaging might provide a solution to some of these challenges.

Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.

Poor responses to iodine-131 (I-131) therapy can relate to either low iodine uptake and retention in thyroid cancer cells or to increased radioresistance. Both mechanisms are currently termed radioactive iodine (RAI)-refractory (RAI-R) thyroid cancer but the first reflects unsuitability for I-131 therapy that can be evaluated in advance of treatment, whereas the other can only be identified post hoc. Management of both represents a considerable challenge in clinical practice as failure of I-131 therapy, the most effective treatment of metastatic thyroid cancer, is associated with a poor overall prognosis.

Can [F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer?

Purpose: To evaluate whether PET/CT could be used to assess the extent of colorectal peritoneal metastases.

Methods: All patients who underwent a PET/CT scan before a CRS-HIPEC procedure between January 1, 2010 and December 31, 2013 were retrospectively included (n = 35). Two nuclear medicine physicians (observer 1 and observer 2) separately reviewed the scans on intraperitoneal abnormalities.

Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by H MRS.

Purpose: A relatively high signal for choline-containing compounds (total choline, tCho) is commonly found in H MR spectra of malignant tumors, but it is unclear if this also occurs in tumors in the liver. We evaluated the potential of the tCho signal in single voxel H MR spectra of the human liver to assess metastases of colorectal cancers.

Experiment: MR spectra of an 8 cm PRESS-localized voxel were obtained at 3 T from the livers of 12 healthy volunteers and from metastatic lesions in 20 patients in two different sessions.

F-FDG PET/CT in Local Ablative Therapies: A Systematic Review.

Driven by the continuous improvement in the accuracy of cross-sectional imaging, image-guided minimally invasive local ablative therapies have received incremental interest over the past few years. In this article, we systematically review the currently available literature on F-FDG PET/CT to monitor the efficacy of these local ablative therapies. By including all local ablative treatment modalities, tumor types, and organ sites, we provide a comprehensive overview of the current status, identify general patterns across studies, and provide recommendations for future studies and clinical practice.

Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions.

The purpose of this work was to improve dynamic contrast enhanced MRI (DCE-MRI) of liver lesions by removing motion corrupted images as identified by a structural similarity (SSIM) algorithm, and to assess the effect of this correction on the pharmacokinetic parameter K using automatically determined arterial input functions (AIFs). Fifteen patients with colorectal liver metastases were measured twice with a T weighted multislice 2D FLASH sequence for DCE-MRI (time resolution 1.2 s).

Half-time bone scintigraphy in prostate and breast cancer patients.

Background: Developments in image reconstruction techniques for planar imaging, also known as enhanced planar processing (EPP), enable the possibility to reconstruct planar scintigraphic images with low count statistics, providing the opportunity to reduce image acquisition time. In this study, the performance of EPP for oncologic half-time bone scintigraphy images was evaluated.

Methods: The EPP software was evaluated for different imaging conditions using standardized phantom experiments.

Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.

Aim: Aim of this study was to investigate the potential of 18F-FDG PET, diffusion weighted imaging (DWI) and susceptibility-weighted (T2*) MRI to predict response to systemic treatment in patients with colorectal liver metastases. The predictive values of pretreatment measurements and of early changes one week after start of therapy, were evaluated.

Methods: Imaging was performed prior to and one week after start of first line chemotherapy in 39 patients with colorectal liver metastases.

Quantification of patient-specific assay interference in different formats of enzyme-linked immunoassays for therapeutic monoclonal antibodies.

Background: The use of therapeutic monoclonal antibodies for clinical purposes has significantly increased in recent years, and so has the need to monitor antibody concentrations. This may be achieved using the well-established enzyme linked immunoassay (ELISA) methods; however, these assays are subject to a variety of interferences.

Methods: In the present study, the authors have tested the ELISA methods for quantifying bevacizumab (BVZ) to investigate this interference.

Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.

Purpose: Several studies showed potential for monitoring response to systemic therapy in metastatic colorectal cancer patients with (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET). Before (18)F-FDG PET can be implemented for response evaluation the repeatability should be known. This study was performed to assess the magnitude of the changes in standardized uptake value (SUV), volume and total lesion glycolysis (TLG) in colorectal liver metastases and validate the biological basis of (18)F-FDG PET in colorectal liver metastases.

Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?

Background: The efficacy of anticancer therapy is usually evaluated by anatomical imaging. However, this method may be suboptimal for the evaluation of novel treatment modalities, such as targeted therapy. Theoretically, functional assessment of tumour response by diffusion weighted imaging (DWI) is an attractive tool for this purpose and may allow an early prediction of response.

Encouraging results in older patients receiving chemotherapy: a retrospective analysis of treatment guideline adherence in daily practice.

Objective: A retrospective study was performed to determine whether patients over 60 years old who received chemotherapy were treated according to the existing treatment guidelines and to investigate the reasons for dose reductions or treatment delay.

Material And Methods: Three hundred and seven patients aged over 60 years old and diagnosed with colon, breast or lung cancer between 1998 and 2008 who were treated with chemotherapy in the Radboud University Medical Center were included. From the medical records we recorded the number of and the reasons for dose reductions and delays.